A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Qilu Pharmaceutical Co., Ltd.
AstraZeneca
Eli Lilly and Company
Blueprint Medicines Corporation
Eli Lilly and Company
Merck Sharp & Dohme LLC
AstraZeneca
Ohio State University Comprehensive Cancer Center